Berlin, 23 March 2020
Accelero Bioanalytics GmbH (“Accelero”) has received the authority permit for processing and analysis of SARS-CoV-2 in biological samples.
The Berlin State Office for Occupational Safety, Health Protection, and Technical Safety (LAGetSi) as well as the local Health Department in Treptow-Köpenick both allowed the processing and analysis of upper and lower respiratory specimen (swaps, sputum, bronchoalveolar lavage) via SARS-CoV-2 specific RTqPCR assays.
The company will also work on immunological assays for innate immune response monitoring like IgG and/or IgM detection and titer determination against SARS-CoV-2 in human serum.
Accelero can also provide FluoroSpot assays for direct and sensitive detection of IgG secreting cells in response to SARS-CoV-2 stimulation in vitro.
All services will be provided in full compliance to Good Laboratory Practice (GLP) regulations.
NOT FOR DIAGNOSTIC USE – FOR INFORMATION PURPOSES ONLY.
Please click hereto download the complete press release including a figure with SARS-CoV-2 RNA genomic organisation.
The figure shows the genomic organization of a SARS-CoV-2 RNA genome isolated and sequenced from a patient in a Japanese cruise ship (Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2/Hu/DP/Kng/19-027 RNA, complete genome. Acc. No. LC528233, Hishiki T et al, 29-FEB-2020).
Accelero provides three different assay formats:
(1) Three RTqPCR assays published by Institut Pasteur, Paris, FRANCE, targeting the genes RdRp IP2, RdRp IP4 and E, respectively.
(2) Three RTqPCR assays published by the CDC, Atlanta, UNITED STATES, targeting the nucleocapsid phosphoprotein.
(3) Three RTqPCR assays published by the Charité, Berlin, GERMANY, targeting the genes RdRp and E, respectively.
A sample is supposed to be positive for SARS-CoV-2 only if all three consecutive assays give a positive signal within the assay acceptance criteria.